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Effects of repeated doses of scopolamine on the 
electroencephalographic stages of sleep in normal volunteers 
Single doses of scopolamine markedly alter sleep patterns in man. This study intended 
to evaluate the persistence of these changes during continued administration. The 
design consisted of a sequence of habituation, no-medication, su!il1e (control), 
scopolamine (0.006 mg/kg intramuscularly 3 consecutive nights), and saline. The first dose 
of scopolamine markedly retarded the onset of stage rapid eye movement (REM) sleep 
(p < 0.005) and diminished the total amount of REM sleep during the night (p < 0.025). 
A decrease in total number of eye movements (p < 0.05) and an increase in body 
movements (p < 0.025) were also observed. Changes after the second dose of scopolamine 
were less marked but still significant. The third dose of scopolamine produced less marked 
changes than the preceding two. When compared with the first scopolamine night, the onset 
of stage REM was retarded to a lesser extent (p < 0.05) and the total amount of REM sleep 
was increased (p < 0.05). An increase in the duration of the first REM period was 
also observed. Rebound effects on the appearance of the first REM period (p < 0.01), 
number of eye movements (p < 0.001), total amount of REM sleep (p < 0.01), and 
body movements were observed in the last saline night. 
T. Sagahf!s, M.D., S. Erin, M.D., and E. F. Domino, M.D. Ann Arbor, Mich., and 
Barcelona, Spain 
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The modification of the normal electroen-
cephalographic (EEG) patterns of sleep by a 
variety of drugs is well documented. It has been 
the subject of several comprehensive reviews. 9, 
11 Drugs affecting the EEG stages of sleep in 
man include various categories of centrally 
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acting agents and, notably, substances with 
marked activity on central cholinergic7, 18 and 
serotonergic5, 21 pathways. One aspect that has 
received some attention is the possible de-
velopment of tolerance toward the drug-induced 
alteration of the sleep stages on continuing 
administration, and the appearance of rebound 
effects on withdrawal. Reports concerning 
tolerance and withdrawal effects have been 
scarce and in some cases of a rather anecdotal 
character. The existence of these effects has 
been challenged in the case of barbiturates, 6 a 
series of drugs for which tolerance and with-
drawal phenomena had been claimed. 8, 14 
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Fig. 1. Effects of nightly scopolamine on the distribution of the stages of sleep in humans . Each 
stage of sleep for each min of 3 volunteers is represented in block format. The mean stages of 
sleep are represented as the thickness of the block and its duration by its length. Note that scopola-
mine decreased the per cent of REM sleep and prolonged the time to first REM. With each subse-
quent dose the effect was less (tolerance), and following the last injection (saline) a REM rebound 
was observed. 
This study was undertaken to explore 
whether tolerance to the effects on the EEG 
patterns of sleep developed after successive 
doses of scopolamine, a drug with clear-cut 
central effects, and whether any rebound was 
apparent upon interruption of the treatment. 
Methods 
Three healthy young males 21, 23, and 25 
years of age participated in the experiment after 
a complete history and physical examina-
tion had been obtained. Well-organized alpha 
rhythm in the occipital areas during a resting 
EEG was present in all cases. The participants 
were instructed to abstain from alcohol or any 
other pharmacologically active substance other 
than coffee or tobacco during the study and in 
the 24 hr prior to its beginning. Coffee or 
tobacco was not permitted after 7 P.M. The 
recordings were made in a sound-attenuated, 
temperature-controlled room. The first night of 
the study was used for habituation; electrodes 
for polygraphic recordings were placed but a 
continuous all-night recording was not ob-
tained, although this was not known by the par-
ticipants. After this night a sequence of 0.9% 
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Table I. Effects of saline and scopolamine on stages of sleep in man 
Stages of sleep (mean per cent ± SE) 
Drug W I II l/l REM 
Saline 12.7 ± 6.0 .3.8 ± 1.7 35.7 ± 6.5 10.2 ± 1.5 15.9 ± 1.4 23.7 ± 2.9 
Scopolamine, 9.5 ± 5.1 10.2 ± 4.1 46.5 ± 6.0 6.2 ± 0.3 17.1 ± 2.1 10.2 ± 1.4* 
first dose 
Scopolamine, 11.1 ± 2.8 17.8 ± 10.0 41.3 ± 10.7 3.7 ± 0.9t 18.1 ±1.3 7.9 ± 1.1 t 
second dose 
Scopolamine, 9.1 ± 4.4 21.9 ± 8.8 
third dose 
Saline 5.9 ± 0.1 3.2 ± 2.8 




NaCl (saline), scopolamine (0.4 mg) for 3 
consecutive nights, and saline followed in 
each case. Injections were given low in the 
deltoid muscle and the volume was 1.2 ml 
in all cases. The sequence used was not 
known either by the subjects or by the tech-
nician monitoring the all-night recording. Sub-
jects entered the sleep laboratory at 9:45 P.M., 
and application of the polygraph electrodes was 
begun immediately. In all cases a calibration 
record was made before 11:00 P.M., and at this 
time the scheduled injection was given in ac-
cordance with the above-described experi-
mental design. Lights in the sound-attenuated 
chamber were turned off after the drug ad-
ministration, and a continuous polygraph 
recording was begun. During all recording 
periods the room temperature was kept at a 
comfortable level, according to individual sub-
ject preferences, and every effort was made to 
achieve a comfortable and as natural as possible 
environment for each individual. An intercom 
was available for two-way communication. At 
6:30 A.M. the subjects were awakened and the 
recording interrupted. 
At the beginning of each recording night, 
silver disc scalp electrodes were placed at posi-
tions F3 , C3 , C4 , P3 , and 0 1 as defined by the 
10-20 International System. Beckman self-
adhesive electrodes placed at FpJ, the outer 
canthi of both eyes, and submentally. These 
served as ground, electrooculogram (EOG), and 
electromyogram (EMG), respectively. Two Te-
lectrode self-adhesive electrodes placed on the 
lobule of each ear and connected together 
served as reference. EEG, EMG, and EOG 
3.9 5.5 ± 1.9 18.5 ± 0.5 15.4 ± 1.2 
4.1 8.5 ± 1.0 15.8 ± 2.6 36.9±3.lt 
were recorded on an 8-channel Grass polygraph 
placed outside the sleeping chamber. Paper 
speed was 15 mm per second and a calibration 
of 50 f.L V per centimeter was used in the EEG 
channels. The calibration of the EMG recording 
was 10 f.L V per centimeter and that of the EOG 
was 100 f.L V per centimeter. 
All sleep records were coded and scored 
without knowledge of the treatment given in 
each case. Modified criteria of Dement and 
Kleitman4 and Williams, Agnew, and Webb20 
were used for scoring as described in a previous 
pUblication. 18 
Results 
The overall pattern of sleep of the partici-
pant subjects in the 5 consecutive nights is 
presented in Fig. 1. The x axis represents the 
number of subjects in a given stage of sleep; 
1 small square represents 1 subject. Quantita-
tive data for each stage of sleep are given in 
Tables I to III. The first dose of scopolamine 
markedly retarded the onset of REM sleep 
(from 126.0 ± 8.4 min in the initial, i.e., con-
trol saline night, to 301.2 ± 9.0 min, p < 
0.005) and diminished the total amount of REM 
sleep during the night (from a mean per cent 
of 23.7 ± 2.9 to 10.2 ± 1.4, P < 0.025). 
The total number of episodes of REM was 
reduced (from 4.0 ± 0.6 to 2.0 ± 0.6) and a 
decrease in the total number of eye movements 
(p < 0.025) was also observed. The duration 
of the first REM period was not affected. 
Changes induced by the second dose of sco-
polamine were similar and also significant when 
compared with the control night. However, 
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Table II. Effects of saline and scopolamine on mean per cent of NREM, REM, BM, 
and number of eye movements 
Total number of 
rapid eye 
Drug N NREM REM BM movements 
Saline 3 72.4 ± 5.6 23.7 ± 2.9 0.2 ± 0.2 681.6 ± 152.6 
Scopolamine, first dose 3 80.2 ± 5.1 10.1 ± 1.4* 5.0 ± 1.2* 242.0 ± 36.3* 
Scopolamine, second dose 3 79.4 ± 1.5 7.9±l.lt 5.3 ± 0.8:1: 309.3 ± 49.9 
Scopolamine, third dose 3 75.5 ± 5.5 15.4 ± l.3~ 3.9 ± 0.9 365.6 ± 94.1§ 
Saline 2 57.2 ± 3.2 36.9±3.lt O±O 1773.5 ± 82.0:1: 
Difference from first saline night: *p < 0.025; tp < 0.001; :j:p < 0.005; §p < 0.05. 
Difference from first scopolamine night: ~ p < 0.005. 
N: number of subjects. 
NREM: non-REM. 
REM: rapid eye movements. 
BM: body movements. 
Table III. Effects of saline and scopolamine on number of episodes of REM, REM latency, 
duration of the first REM period, and REM minutes by thirds of night in the sleep of man 
Number of RE M minutes by thirds of night 
REM REM Duration of I I Drug episodes latency first RE M period First Second Third 
Saline 4.0 ± 0.6 126.0 ± 8.4 15.0 ± 5.5 8.7 ± 0.7 36.0 ± 2.9 62.0 ± 11.0 
Scopolamine, 2.0 ± 0.6 301.2 ± 9.0* 10.3 ± 4.1 t 0 0 46.0 ± 6.0 
first dose 
Scopolamine, 1.6 ± 0.3 340.2 ± 12.0* 30.3 ± 7.7 0 0 36.0 ± 4.6 
second dose 
Scopolamine, 2.3 ± 0.3t 262.2 ± 12.6:1: 37.0 ± 10.9 0 17.7 ± 8.4 51.3 ± 7.0 
third dose 
Saline 3.5 ± 0.5 103.3 ± II.4t 
Difference from first saline night: *p < 0.005; tp < 0.05. 
Difference from first scopolamine night: :j:p < 0.05. 
33.5 ± 
an increase in the duration of the first REM 
period was observed. This increase was signifi-
cant compared to the control night (p < 0.05). 
The third consecutive dose of scopolamine pro-
duced less marked changes than the preceding 
two, particularly with regard to total REM 
inhibition and REM latency (p < 0.05 when 
compared with the first scopolamine night, in 
both cases). REM sleep was already detected 
during the second third of the night. The ex-
tended duration of the first REM period ob-
served during the second scopolamine night 
was still present. 
Administration of saline after 3 consecutive 
doses of scopolamine produced rebound effects 
on latency and amount of REM sleep (p < 0.05 
and p < 0.01, respectively). The increase in 
REM sleep was observed throughout the night 
6.5t 31.5 ± 4.5 50.5 ± 11.5 84.0 ± 7.0 
but was particularly marked in the first third of 
it (p < 0.01 when compared with the same 
period of the control night). 
There were also rebound effects on total 
number of eye movements (p < 0.005). The 
duration of the first REM period was longer 
than in the control night (p < 0.05), as it was 
in the preceding two nights. 
Discussion 
In recent years there have appeared several 
reports concerning the possible development 
of tolerance and rebound phenomena in the 
effects of drugs on the EEG patterns of 
sleep.!' 8, 10, 14 Most of these studies dealt with 
the effects of barbiturates, and comparisons 
between successive daily doses in this cate-
gory of drugs should be regarded with some 
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caution. On one hand, the long half-life of most 
barbiturates19 would tend to account for quite 
different plasma levels on the consecutive 
nights and, on the other, the well-known 
enzyme-inducing properties of the long-acting 
members of this class16 may account also for 
important changes in their kinetics, although 
in an opposite way. The actual availability of 
successive doses is difficult to predict and may 
well vary according to the compound used or 
the size of the dose. Therefore, it is not sur-
prising that results concerning effects of these 
drugs on the EEG sleep cycles in man have 
been conflicting. 6, 8 Tolerance and withdrawal 
effects have also been described following 
amphetamine and some of its derivatives, but 
the interpretation of these results is somewhat 
difficult since the available studies have dealt 
with addicts15 or lack enough data and statisti-
cal analysis. 13 
The results of our study confirm earlier 
findings on the acute effects of scopolamine on 
the EEG stages of sleep in man18 and con-
tribute some evidence concerning the develop-
ment of tolerance and rebound phenomena. It 
is interesting to note that the duration of the 
first REM period was already above the control 
values after the second dose of scopolamine 
and that this change persisted even after dis-
continuation of the treatment. Furthermore, 
there was distinct tolerance to the inhibition of 
the total amount of REM sleep and to the in-
crease in REM latency with the third consecu-
tive dose of scopolamine. 
Rebound effects were also detected, both on 
REM latency and total amount of REM sleep. 
The shortening of REM latency, although 
small, was significant and was accompanied by 
a striking increase in the amount of REM stage 
in the first third of the night. Total amount of 
REM sleep was increased above control values 
and so was the total number of REMs. It has 
been suggested that REM sleep indicates in-
creased protein synthesis in the brain and that 
REM sleep is a nonspecific indicator of many 
forms of synthesis in the brain. 12 Our knowl-
edge of the physiology of sleep is probably 
not sufficient to warrant acceptance or rejection 
of this hypothesis, but increased synthesis 
of transmitter following receptor blockade 
Scopolamine and sleep 731 
could perhaps be postulated to explain some 
cases of tolerance and withdrawal effects in 
sleep. Accumulation of acetylcholine in cholin-
ergic nerve terminals has been demonstrated 
following blockade of its release in the guinea 
pig ileum,17 and increases in the synthesis of 
neurotransmitters very shortly after receptor 
blockade are well documented in the adrenergic 
and dopaminergic systems. 2, 3 We believe that 
our data, as well as those of other studies 
using different drugs with specific and clear-cut 
central effects, may help to elucidate the or-
ganization of sleep in man and the nature of its 
pharmacologic responsiveness. 
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